A study by researchers at the University of Sussex has shown the potential for benefiting leukemia patients by developing new treatment strategies.
M myeloid leukemia AML is a type of leukemia that affects a type of leukocyte that is responsible for fighting infection and preventing tissue damage. There are almost 3,000 new cases of AML in the UK each year, but the disease is contagious uncertainty and many relapses, as current chemotherapies are both toxic and ineffective.
But now, researchers have discovered that two major oncoproteins can interact internally leukemia bacteriaaffects the function of the oncogenic signaling pathways — that is, their ability to modulate genes and lead to bacterial growth.
Dr Rhys Morgan, Lecturer in Biological Sciences at the University of Sussex, and Director of the Hematology Research Center of Sussex, said: treatment also helps us better understand how the disease progresses.
“We have long known that each of these oncoproteins contributes to the development of leukemia but it is not fully understood how, which hinders the development of treatment. This study shows for the first time that these ‘heavy’ ones the two in leukemia are interrelated and highly effective.reactions in AML cells.
“Beta-catenin signaling is highly regulated in AML, but this oncogenic activity is strongly influenced by what other molecules it interacts with in cancer cells.
“For the first time, we were able to open a beta-catenin interaction network in leukemia cells and discovered that it interacts with a well-known signaling protein called Wilms Tumor 1 (WT1). Pediatric kidney cancer called Wilms Tumors but also overreacting and changing in AML. ”
The results of their study, published in Haematology, the field’s leading newspaper, should offer hope to leukemia sufferers. To date, beta-catenin-targeted treatments have shown limited success, and Dr. Morgan and his team believe that treatments that focus on disrupting its interactions with other proteins, may have a greater potential.
Dr. Morgan explained: “The next step in this study is to try to understand exactly how the interaction of these two proteins contributes to the development of leukemia and then to work with biologists and pharmacologists to formulate strategies for how this can be done. can be disrupted by healing.
“Statistics from our team at the University of Sussex, among others, show that between 40-80% of cases of AML show some beta-catenin levels. A large number of patients with AML — but also later.”
“Such research does not take place without the contribution of leukemia or routine cancer Cells from patients and donors, so I want to extend my gratitude to all those who have allowed meat to be used in medical research. ”
Crosstalk between b-catenin and WT1 signal functions in acute myeloid leukemia, Hematology (2022).
University of Sussex
hintScientists have discovered new genetic techniques to treat the malignant form of leukemia (2022, April 21) retrieved April 21, 2022 from https://medicalxpress.com/news/2022-04-scientists-molecular-strategies -tackling-aggressive.html
This document is copyrighted. Apart from any genuine transaction for the purpose of personal analysis or investigation, no part may be reproduced without our written permission. Content is provided for informational purposes only.
Scientists identify new molecular strategies for tackling aggressive form of leukemia Source link Scientists identify new molecular strategies for tackling aggressive form of leukemia